Health Care [ 11/12 ] | Biotechnology [ 66/74 ]
NASDAQ | Common Stock
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.
The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma.
The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM.
Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 5, 25 | -0.30 Increased by +49.15% | -0.29 Decreased by -3.45% |
| Mar 5, 25 | -0.30 Increased by +47.37% | -0.28 Decreased by -5.26% |
| Oct 31, 24 | -0.31 Increased by +8.82% | -0.44 Increased by +29.55% |
| Aug 8, 24 | -0.45 Increased by +35.71% | -0.65 Increased by +30.77% |
| May 6, 24 | -0.59 Increased by +19.18% | -0.63 Increased by +6.35% |
| Mar 7, 24 | -0.57 Increased by +17.39% | -0.76 Increased by +25.00% |
| Nov 2, 23 | -0.34 Increased by +45.16% | -0.75 Increased by +54.67% |
| Aug 4, 23 | -0.70 Decreased by -6.06% | -0.73 Increased by +4.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 2.86 M Decreased by -50.49% | -19.50 M Increased by +19.09% | Decreased by -682.88% Decreased by -63.43% |
| Sep 30, 24 | 7.81 M Decreased by -55.33% | -19.12 M Decreased by -33.30% | Decreased by -244.90% Decreased by -198.39% |
| Jun 30, 24 | 6.89 M Increased by +23.02% | -22.98 M Increased by +22.07% | Decreased by -333.61% Increased by +36.65% |
| Mar 31, 24 | 5.05 M Decreased by -4.88% | -25.02 M Increased by +17.95% | Decreased by -495.37% Increased by +13.74% |
| Dec 31, 23 | 5.77 M Increased by +37.88% | -24.11 M Increased by +29.38% | Decreased by -417.85% Increased by +48.78% |
| Sep 30, 23 | 17.48 M Increased by +163.46% | -14.35 M Increased by +38.38% | Decreased by -82.07% Increased by +76.61% |
| Jun 30, 23 | 5.60 M Increased by +24.70% | -29.49 M Decreased by -7.96% | Decreased by -526.65% Increased by +13.42% |
| Mar 31, 23 | 5.31 M Increased by +35.43% | -30.49 M Decreased by -17.15% | Decreased by -574.27% Increased by +13.50% |